Xceleron, a provider of analytical strategies for drug development, will expand its U.S. business by signing of a lease on a facility in Germantown, MD. The facility, opening in November 2007, will house a new accelerator mass spectrometer (AMS) and employ at least 20 people in scientific, commercial and administrative roles.
Professor Colin Garner, Xceleron's chief executive officer, commented, "This is a major strategic development in the evolution of our company. We will invest as much as $7.5 million on the purchase of a new AMS and associated equipment to carry out analysis on pharmaceutical drug candidates. Our new facility will allow us to substantially increase our development capacity to better serve our customers worldwide." The company began U.S. operations in 2005.
Magazine
